Optimal organogenesis without teratoma depends on distinct time windows. Proceedings of the National Academy of Sciences 102(8): 2928–2933. 9. Haylock D, Nilsson S (2005) Stem cell regulation by the hematopoietic stem cell niche. Cell Cycle 4(10): 1353–5. 10. Haylock D, Nilsson S (2006) Osteopontin: a bridge between bone and blood. Br J Haematol 134(5): 467–74. 11. Aronovich A, Tchorsh D, Katchman H, Eventov-Friedman S, Shezen E, et al. (2006) Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proceedings of the National Academy of Sciences 103(50): 19075–19080. 12. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, et al. (1992) RAG-2- deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68(5): 855–67. 13. Croce K, Libby P (2007) Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 14(1): 55–61. 14. Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, et al. (2009) Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circ Res 105(3): 214–8. 15. Martorell L, Mart´ınez-Gonza´lez J, Rodr´ıguez C, Gentile M, Calvayrac O, et al. (2008) Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 99(2): 305–15. 16. Hirano K (2007) The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 27(1): 27–36. 17. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L (1994) Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5(5): 565–74. 18. Senger DR, Perruzzi CA (1996) Cell migration promoted by a potent GRGDS- containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1314(1–2): 13–24. 19. Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L (1995) Osteopontin at the tumor/host interface.Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci 760: 83–100. 20. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, et al. (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106(4): 1232–9. 21. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, et al. (2009) Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114(1): 49–59. Organ Size Control 22. Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, et al. (2008) Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 7(9): 2746–57. 23. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C (2003) Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Des 9(28): 2349–65. 24. Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, et al. (2007) Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 110(9): 3176–82. 25. Wielders SJ, Bennaghmouch A, Reutelingsperger CP, Bevers EM, Lindhout T (2007) Anticoagulant and antithrombotic properties of intracellular protease- activated receptor antagonists. J Thromb Haemost 5(3): 571–6. 26. Coughlin S (2000) Thrombin signalling and protease-activated receptors. Nature 407(6801): 258–64. 27. Landis R (2007) Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 21(1): 103–13. 28. Kelleher FC, Fennelly D, Rafferty M (2006) Common critical pathways in embryogenesis and cancer. Acta Oncol 45(4): 375–88. 29. Coughlin S (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3(8): 1800–14. 30. Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10(5): 355–62. 31. Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32 Suppl 1: 61–8. 32. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Gru¨newald E, et al. (2005) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201(11): 1781–91. 33. Forsberg EC, Bhattacharya D, Weissman IL (2006) Hematopoietic stem cells: expression profiling and beyond. Stem Cell Rev 2(1): 23–30. 34. Papayannopoulou T, Scadden DT (2008) Stem-cell ecology and stem cells in motion. Blood 111(8): 3923–30. 35. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM (2008) Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res 314(9): 1937–44. 36. Dekel B, Burakova T, Arditti FD, Reich-Zeliger S, Milstein O, et al. (2003) Human and porcine early kidney precursors as a new source for transplantation. Nature Medicine 9(1): 53–60. 37. Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, et al. (2008) Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab 28(6): 1235–48. PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8362